パクリタキセルの用量調節により治療継続が可能となった重度肝障害を伴う同時性肝転移両側乳がんの1例
「緒言」転移・再発乳がんの治療の中心は薬物療法であり, 薬物療法は内分泌療法, 化学療法, 抗human epidermal growth factor receptor type 2(HER2)療法に大別される. これらは腫瘍のサブタイプ(estrogen receptor: ER, progesterone receptor: PgR, HER2等), 転移臓器とその広がり, 治療開始時点での症状の有無, 治療歴等を考慮して単独もしくは併用により実施される. 一般に, 内分泌療法は化学療法よりも副作用が軽度であるため, ホルモン受容体陽性乳がんの場合は, 内分泌療法が優先される. しかしな...
Saved in:
| Published in | 医療薬学 Vol. 47; no. 4; pp. 217 - 224 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人日本医療薬学会
10.04.2021
日本医療薬学会 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1346-342X 1882-1499 |
| DOI | 10.5649/jjphcs.47.217 |
Cover
| Abstract | 「緒言」転移・再発乳がんの治療の中心は薬物療法であり, 薬物療法は内分泌療法, 化学療法, 抗human epidermal growth factor receptor type 2(HER2)療法に大別される. これらは腫瘍のサブタイプ(estrogen receptor: ER, progesterone receptor: PgR, HER2等), 転移臓器とその広がり, 治療開始時点での症状の有無, 治療歴等を考慮して単独もしくは併用により実施される. 一般に, 内分泌療法は化学療法よりも副作用が軽度であるため, ホルモン受容体陽性乳がんの場合は, 内分泌療法が優先される. しかしながら, 急速な病状の進行や広範な臓器転移等により差し迫った生命の危機がある場合においては, 化学療法を導入することが, 乳癌診療ガイドライン2018(2019追補版)(乳癌ガイドライン)でも推奨されている. 転移・再発乳がんの一次化学療法としては, タキサン系もしくはアンスラサイクリン系抗がん薬が推奨される. |
|---|---|
| AbstractList | 「緒言」転移・再発乳がんの治療の中心は薬物療法であり, 薬物療法は内分泌療法, 化学療法, 抗human epidermal growth factor receptor type 2(HER2)療法に大別される. これらは腫瘍のサブタイプ(estrogen receptor: ER, progesterone receptor: PgR, HER2等), 転移臓器とその広がり, 治療開始時点での症状の有無, 治療歴等を考慮して単独もしくは併用により実施される. 一般に, 内分泌療法は化学療法よりも副作用が軽度であるため, ホルモン受容体陽性乳がんの場合は, 内分泌療法が優先される. しかしながら, 急速な病状の進行や広範な臓器転移等により差し迫った生命の危機がある場合においては, 化学療法を導入することが, 乳癌診療ガイドライン2018(2019追補版)(乳癌ガイドライン)でも推奨されている. 転移・再発乳がんの一次化学療法としては, タキサン系もしくはアンスラサイクリン系抗がん薬が推奨される. |
| Author | 佐々木, 均 兒玉, 幸修 福嶋, 絢子 原澤, 仁美 中川, 博雄 里, 加代子 大坪, 竜太 中村, 忠博 松本, 恵 橋詰, 淳哉 矢野, 洋 永安, 武 |
| Author_xml | – sequence: 1 fullname: 中村, 忠博 organization: 長崎大学病院 薬剤部 – sequence: 1 fullname: 兒玉, 幸修 organization: 長崎大学病院 薬剤部 – sequence: 1 fullname: 松本, 恵 organization: 長崎大学病院 腫瘍外科 – sequence: 1 fullname: 里, 加代子 organization: 長崎大学病院 薬剤部 – sequence: 1 fullname: 福嶋, 絢子 organization: 長崎大学病院 腫瘍外科 – sequence: 1 fullname: 原澤, 仁美 organization: 長崎大学病院 薬剤部 – sequence: 1 fullname: 佐々木, 均 organization: 長崎大学病院 薬剤部 – sequence: 1 fullname: 中川, 博雄 organization: 長崎大学病院 薬剤部 – sequence: 1 fullname: 橋詰, 淳哉 organization: 長崎大学病院 薬剤部 – sequence: 1 fullname: 矢野, 洋 organization: 長崎大学病院 腫瘍外科 – sequence: 1 fullname: 永安, 武 organization: 長崎大学病院 腫瘍外科 – sequence: 1 fullname: 大坪, 竜太 organization: 長崎大学病院 腫瘍外科 |
| BookMark | eNo1kd9q1EAUxgepYK299DGyzmQmk-ROKVqFgjcVvBtmk4lN2M0uSb3wrjMLVrS2_rvZoogKtmyxC7YUddU-zNlsdt_CqdWb75zDx_l9HM5lNJd3coXQVYIbHmfhtSzrrkVlg_kNl_gX0DwJAtchLAznbE8Zdyhz719Ci2WZNjGmhHDihfNoG3ovwQyhNwBzCuYLmBH0DkAf1m_2Z5s708FpPdwAfQDmCZink6-jum_qk359sgt6q9oZTnu_QO-DHoD-BPr9bPN59ePz1Lyb7b6tDo_AvBr_PAb9uHqxNembycaetaajj_XeaPztQ6WPx9-PLAfMa5tIxr-fXUEXE9kq1eK_uoDu3bq5unTbWbm7fGfpxoqTUYKZEyrGcZxgqUIe8ChSiT1ReYpSL1EMM4xDzO3RTcqTOJCMBrFPfE6bnowjRV26gJbPuW0Vp5FsdfJWmiuRdR4Wuc0VcdPrrsmiLVzsEoEx8zGzhQs7-lZcRv2A4IBa0vVzUlauywdKdIu0LYtHQhbradSyyL9_EcwX7EzO1v9bkU0QmaR_AGYGuvk |
| ContentType | Journal Article |
| Copyright | 2021 日本医療薬学会 |
| Copyright_xml | – notice: 2021 日本医療薬学会 |
| CorporateAuthor | 長崎大学病院 薬剤部 長崎大学病院 腫瘍外科 |
| CorporateAuthor_xml | – name: 長崎大学病院 薬剤部 – name: 長崎大学病院 腫瘍外科 |
| DOI | 10.5649/jjphcs.47.217 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1882-1499 |
| EndPage | 224 |
| ExternalDocumentID | db5pharm_2021_004704_006_0217_02243781083 article_jjphcs_47_4_47_217_article_char_ja |
| GroupedDBID | .LE 5GY ABJNI ALMA_UNASSIGNED_HOLDINGS KQ8 MOJWN RJT |
| ID | FETCH-LOGICAL-j3104-9e460df0ae9686ccef134e5e335fe40400906346b36fd8a438d71763b5adce323 |
| ISSN | 1346-342X |
| IngestDate | Thu Jul 10 16:14:48 EDT 2025 Wed Sep 03 06:30:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 4 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j3104-9e460df0ae9686ccef134e5e335fe40400906346b36fd8a438d71763b5adce323 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjphcs/47/4/47_217/_article/-char/ja |
| PageCount | 8 |
| ParticipantIDs | medicalonline_journals_db5pharm_2021_004704_006_0217_02243781083 jstage_primary_article_jjphcs_47_4_47_217_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20210410 |
| PublicationDateYYYYMMDD | 2021-04-10 |
| PublicationDate_xml | – month: 04 year: 2021 text: 20210410 day: 10 |
| PublicationDecade | 2020 |
| PublicationTitle | 医療薬学 |
| PublicationTitleAlternate | 医療薬学 |
| PublicationYear | 2021 |
| Publisher | 一般社団法人日本医療薬学会 日本医療薬学会 |
| Publisher_xml | – name: 一般社団法人日本医療薬学会 – name: 日本医療薬学会 |
| References | 21）Ishikawa M, Kawai M, Maeda T, Kagawa Y, Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic, Cancer Chemother Pharmacol, 2018, 81, 399-411. 8）櫻井健一, 榎本克久, 天野定雄, 北島 晃, 鈴木昌義, 松尾定憲, 坂本明子, 柏尾光彦, 谷 真弓, 根岸七雄, 集学的治療により良好な経過が得られたStage Ⅳ乳癌の1例, 癌と化学療法, 2005, 32, 1792-1794. 10）吉岡節子, 北條茂幸, 豊田泰弘, 前浦義市, 化学療法＋抗HER2療法が著効したStage IV HER2陽性乳癌の1例, 癌と化学療法, 2017, 44, 1214-1216. 12）Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U, Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application, Sci Pharm, 2017, 85, 8. doi: 10.3390/scipharm85010008. 3）Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N Engl J Med, 2015, 372, 724-734. 17）Rodes Brown S, Martin RC 2nd, Management of liver dominant metastatic breast cancer: surgery, chemotherapy, or hepatic arterial therapy - benefits and limitations, Minerva Chir, 2012, 67, 297-308. 14）Shinoda Y, Kimura M, Usami E, Asano H, Yoshimura T, Potential drug interaction between paclitaxel and clopidogrel, Biomed Rep, 2016, 5, 141-145. 23）Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R, SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions, Nucleic Acids Res, 2010, 38(Database issue), D237-D243. 1）Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 2012, 366, 109-119. 20）中澤佑介, 影山 明, 原田 大, 北村正樹, 三森教雄, 川久保孝, 胃癌に対するPaclitaxel単独療法およびPaclitaxel＋Ramucirumab併用療法時における低アルブミン血症がGrade 3以上の好中球減少症に及ぼす影響, 癌と化学療法, 2019, 46, 901-905. 19）Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH, Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors, Clin Cancer Res, 2006, 12, 2150-2157. 13）Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB, Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study, Br J Clin Pharmacol, 2007, 64, 622-633. 16）Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y, SELECT BC Study Group, Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial, Lancet Oncol, 2016, 17, 90-98. 11）木下春人, 寺岡 均, 森 拓哉, 長谷川毅, 野田英児, 高島 勉, 平川弘聖, 大平雅一, 化学療法が著効した黄疸を伴う乳癌多発肝転移の1例, 癌と化学療法, 2019, 46, 2461-2463. 7）唐司則之, 小林 豊, 斎藤 剛, 清水孝徳, 夏目俊之, 田中 元, 丸山尚嗣, 渡辺義二, Weekly TrastuzumabおよびPaclitaxelが奏効した乳癌肝転移の1例, 癌と化学療法, 2003, 30, 989-992. 9）雷 哲明, 高濱哲也, 相良吉昭, 相良安昭, 松山義人, 安藤充嶽, 相良吉厚, 大井恭代, Bi-Weekly TrastuzumabとPaclitaxelの併用が多発性肝転移を伴う進行乳癌に著効を示した1症例, 癌と化学療法, 2006, 33, 1297-1300. 6）Field KM, Michael M, Part Ⅱ: Liver function in oncology: towards safer chemotherapy use, Lancet Oncol, 2008, 9, 1181-1190. 22）Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL, Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264, J Clin Oncol, 1998, 16, 1811-1819. 5）Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C, PhaseⅡ study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2―positive metastatic breast cancer, J Clin Oncol, 2015, 33, 442-447. 18）Tamura T, Sasaki Y, Nishiwaki Y, Saijo N, Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities, Jpn J Cancer Res, 1995, 86, 1203-1209. 4）Swain SM, Miles D, Kim SB, Im YM, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, CLEOPATRA study group, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, Lancet Oncol, 2020, 21, 519-530. 2）Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 2013, 14, 461-471. 15）Agergaard K, Mau-Sørensen M, Stage TB, Jørgensen TL, Hassel RE, Steffensen KD, Pedersen JW, Milo M, Poulsen SH, Pottegård A, Hallas J, Brøsen K, Bergmann TK, Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study, Clin Pharmacol Ther, 2017, 102, 547-553. |
| References_xml | – reference: 3）Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N Engl J Med, 2015, 372, 724-734. – reference: 11）木下春人, 寺岡 均, 森 拓哉, 長谷川毅, 野田英児, 高島 勉, 平川弘聖, 大平雅一, 化学療法が著効した黄疸を伴う乳癌多発肝転移の1例, 癌と化学療法, 2019, 46, 2461-2463. – reference: 9）雷 哲明, 高濱哲也, 相良吉昭, 相良安昭, 松山義人, 安藤充嶽, 相良吉厚, 大井恭代, Bi-Weekly TrastuzumabとPaclitaxelの併用が多発性肝転移を伴う進行乳癌に著効を示した1症例, 癌と化学療法, 2006, 33, 1297-1300. – reference: 20）中澤佑介, 影山 明, 原田 大, 北村正樹, 三森教雄, 川久保孝, 胃癌に対するPaclitaxel単独療法およびPaclitaxel＋Ramucirumab併用療法時における低アルブミン血症がGrade 3以上の好中球減少症に及ぼす影響, 癌と化学療法, 2019, 46, 901-905. – reference: 15）Agergaard K, Mau-Sørensen M, Stage TB, Jørgensen TL, Hassel RE, Steffensen KD, Pedersen JW, Milo M, Poulsen SH, Pottegård A, Hallas J, Brøsen K, Bergmann TK, Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study, Clin Pharmacol Ther, 2017, 102, 547-553. – reference: 16）Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y, SELECT BC Study Group, Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial, Lancet Oncol, 2016, 17, 90-98. – reference: 19）Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH, Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors, Clin Cancer Res, 2006, 12, 2150-2157. – reference: 14）Shinoda Y, Kimura M, Usami E, Asano H, Yoshimura T, Potential drug interaction between paclitaxel and clopidogrel, Biomed Rep, 2016, 5, 141-145. – reference: 12）Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U, Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application, Sci Pharm, 2017, 85, 8. doi: 10.3390/scipharm85010008. – reference: 1）Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 2012, 366, 109-119. – reference: 5）Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C, PhaseⅡ study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2―positive metastatic breast cancer, J Clin Oncol, 2015, 33, 442-447. – reference: 8）櫻井健一, 榎本克久, 天野定雄, 北島 晃, 鈴木昌義, 松尾定憲, 坂本明子, 柏尾光彦, 谷 真弓, 根岸七雄, 集学的治療により良好な経過が得られたStage Ⅳ乳癌の1例, 癌と化学療法, 2005, 32, 1792-1794. – reference: 7）唐司則之, 小林 豊, 斎藤 剛, 清水孝徳, 夏目俊之, 田中 元, 丸山尚嗣, 渡辺義二, Weekly TrastuzumabおよびPaclitaxelが奏効した乳癌肝転移の1例, 癌と化学療法, 2003, 30, 989-992. – reference: 17）Rodes Brown S, Martin RC 2nd, Management of liver dominant metastatic breast cancer: surgery, chemotherapy, or hepatic arterial therapy - benefits and limitations, Minerva Chir, 2012, 67, 297-308. – reference: 6）Field KM, Michael M, Part Ⅱ: Liver function in oncology: towards safer chemotherapy use, Lancet Oncol, 2008, 9, 1181-1190. – reference: 18）Tamura T, Sasaki Y, Nishiwaki Y, Saijo N, Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities, Jpn J Cancer Res, 1995, 86, 1203-1209. – reference: 13）Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB, Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study, Br J Clin Pharmacol, 2007, 64, 622-633. – reference: 22）Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL, Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264, J Clin Oncol, 1998, 16, 1811-1819. – reference: 2）Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 2013, 14, 461-471. – reference: 21）Ishikawa M, Kawai M, Maeda T, Kagawa Y, Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic, Cancer Chemother Pharmacol, 2018, 81, 399-411. – reference: 4）Swain SM, Miles D, Kim SB, Im YM, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, CLEOPATRA study group, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, Lancet Oncol, 2020, 21, 519-530. – reference: 23）Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R, SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions, Nucleic Acids Res, 2010, 38(Database issue), D237-D243. – reference: 10）吉岡節子, 北條茂幸, 豊田泰弘, 前浦義市, 化学療法＋抗HER2療法が著効したStage IV HER2陽性乳癌の1例, 癌と化学療法, 2017, 44, 1214-1216. |
| SSID | ssib003116159 ssib002484604 ssib000871962 ssib060196744 ssj0069027 ssib005902156 ssib023157658 |
| Score | 2.2335985 |
| Snippet | 「緒言」転移・再発乳がんの治療の中心は薬物療法であり, 薬物療法は内分泌療法, 化学療法, 抗human epidermal growth factor receptor type 2(HER2)療法に大別される. これらは腫瘍のサブタイプ(estrogen receptor: ER, progesterone... |
| SourceID | medicalonline jstage |
| SourceType | Publisher |
| StartPage | 217 |
| SubjectTerms | HER2-positive breast cancer liver dysfunction liver metastasis paclitaxel |
| Title | パクリタキセルの用量調節により治療継続が可能となった重度肝障害を伴う同時性肝転移両側乳がんの1例 |
| URI | https://www.jstage.jst.go.jp/article/jjphcs/47/4/47_217/_article/-char/ja http://mol.medicalonline.jp/en/journal/download?GoodsID=db5pharm/2021/004704/006&name=0217-0224j |
| Volume | 47 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 医療薬学, 2021/04/10, Vol.47(4), pp.217-224 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1di9VGNNjtS6GUWltqrXIfOj55t8mdyWTmrZN77yIWxcIK-xaSm4RyoXbprg_6ZLJQRW3t18uKIlVQWdGFKqLdtv6Y2bt391_0nJlkb64ItfoSDjNnzmcyc04yc-I4n0FMnjGWizbz47wNN4XbjqlP2znHb1wwK8sU30MeP8GPnmLHFvyFPTMnGruWziwns4NzLz1X8jpehTbwK56S_R-e3SUKDQCDf-EKHobrK_mY9CkRlEjPAB2i5qoWpaqWcK7u6tUtYY1jAY-oPukHRDKiBOlLIgIiYJRAIjg8QLLCrZHDio4QNQC8OAktZaAjsRGAkCNcAaoaLrqk7yN9ZViAGGGvpixqoEZWtALkXC1YD4eHiihuhneI7GEX0JeGMugS0kowCWIwEnZJyGruHHGka8TgtagctVNBg6BAXZTRAtpRL6ADBvGM8J4hCC2y5mX1skzprlU9g9QnImxmAIZEd9pYgkhOlFWgB7rVTwHKpgAlNO4Adq4xdWD4-shLyCYuyA78EOgactwI609QAjQlKmataXBBGRFOUEAEZqzhIzn0RYBOr8wLXar5oqjj4TevasswPtqGO4zwG2L8t8KVo6RqrJGU8TZlnYXmImrLplaTBZtaEYNGcNWxB-ZfXLd9zrDs7XC4-PVgaZYFs7ujpkqhp4m_iAXdI1QvwkKnLovMxkzAjzAapYHwIKl4y3m7EwRm28aXXzXTjQAWnEa5PA_znUb5OokR8G54DqkPZOOTXQMca0mZv0XYSI8Duvl5U20QW8MXlfl8ShWIboeQ62ERj3e_sd9fbR2cRig7_77zXpWDtpSdUPY6e4bxB87hk7aI_dkjrfnJmcylI63DrZOT8vZn9zk_6pWfdbmuV9Z0-VyXD3S5oVfu6-Lh-Ld7Oxeubq89H6-f18V9XV7U5aWtPzbGq-X4yer4yTVdXBldXd9e-VsX93Sxpovburi5c-GH0Z93tssbO9eujx4-0uUvm3891sX3o5-ubK2WW-fvQtf2xq3x3Y3Np7-Pisebzx4BHV3-Chy9zX8uf-icmuvPd4-2q7-6tIeQSrI2rA3cTXM3ziQXfDDIcrBf5meU-nnGMKaQkDYxnlCepyJmVKSBB1FQ4sfpIKMd-pEzc_rb09nHTsvLszRNmJdIb8DcxIthFHcpZWmeJJ3Y2-9Ia_do0ZbuiaqpOrLuiVgQMbzg7VN34WnXaBjvd76YclVUzftL0SvfhZ-8OYkDzjuTR_lTZ2b5uzPZQciClpND5tb-F0vrLNk |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%83%91%E3%82%AF%E3%83%AA%E3%82%BF%E3%82%AD%E3%82%BB%E3%83%AB%E3%81%AE%E7%94%A8%E9%87%8F%E8%AA%BF%E7%AF%80%E3%81%AB%E3%82%88%E3%82%8A%E6%B2%BB%E7%99%82%E7%B6%99%E7%B6%9A%E3%81%8C%E5%8F%AF%E8%83%BD%E3%81%A8%E3%81%AA%E3%81%A3%E3%81%9F%E9%87%8D%E5%BA%A6%E8%82%9D%E9%9A%9C%E5%AE%B3%E3%82%92%E4%BC%B4%E3%81%86%E5%90%8C%E6%99%82%E6%80%A7%E8%82%9D%E8%BB%A2%E7%A7%BB%E4%B8%A1%E5%81%B4%E4%B9%B3%E3%81%8C%E3%82%93%E3%81%AE1%E4%BE%8B&rft.jtitle=%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6&rft.au=%E6%A9%8B%E8%A9%B0%E6%B7%B3%E5%93%89&rft.au=%E6%9D%BE%E6%9C%AC%E6%81%B5&rft.au=%E7%9F%A2%E9%87%8E%E6%B4%8B&rft.au=%E5%A4%A7%E5%9D%AA%E7%AB%9C%E5%A4%AA&rft.date=2021-04-10&rft.pub=%E6%97%A5%E6%9C%AC%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6%E4%BC%9A&rft.issn=1346-342X&rft.volume=47&rft.issue=4&rft.spage=217&rft.epage=224&rft_id=info:doi/10.5649%2Fjjphcs.47.217&rft.externalDocID=db5pharm_2021_004704_006_0217_02243781083 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-342X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-342X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-342X&client=summon |